Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06208878 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 22 to 24
    • Secondary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 3 words
  2. Study sites: 21 to 22v11
  3. Study sites: 16 to 21v10
  4. Study sites: 13 to 16v9
  5. Study sites: 12 to 13v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 9 to 12v7
  2. Study sites: 7 to 9v6
  3. Study sites: 6 to 7v5
  4. Study sites: 4 to 6v4
  5. Study sites: 3 to 4v3
  6. Study sites: 2 to 3v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
Trial Details
NCT Number NCT06208878
Lead Sponsor CRISPR Therapeutics AG
Conditions
(from sponsor)		 Hematologic Malignancy, Solid Malignancy
Related terms Hematologic Neoplasms
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov